What Happened

uniQure reported preliminary six-month data from its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. Three of six patients in the low-dose cohort experienced a 79%-100% reduction in disabling seizures, with no serious adverse events reported.

Who Is Affected

Patients with refractory mesial temporal lobe epilepsy and biotech companies focused on gene therapy or epilepsy treatments are directly impacted by this development.

Market Impact

• Early success in AMT-260 could position uniQure as a leader in gene therapy for epilepsy.
• Investors may react positively to clinical updates, given historical stock performance around similar announcements.
• Competitors in the epilepsy treatment space may face increased pressure to innovate.

What to Watch

Enrollment in the higher-dose cohort is ongoing, with updated results expected in early 2027. Continued monitoring of safety and efficacy data will be critical for AMT-260’s progression.